Probing depth changes following 2 years of periodontal maintenance therapy including adjunctive controlled release of XXXX .

@entity1 @entity1216 @entity548 @entity7278 @entity92
BACKGROUND: Multicenter clinical trials have established that the adjunctive use of the subgingival controlled release of @entity1216 , (CHX chip), significantly reduces @entity92 ( @entity92 ), improves clinical attachment levels, and reduces @entity548 on probing compared to scaling and root planing (SRP) alone for periods of up to 9 months. The present report is based on a phase IV clinical trial to examine the adjunctive use of the CHX chip for routine periodontal maintenance therapy (RPMT) over 2 years. METHODS: Eight hundred thirty-five (835) @entity1 were recruited into the study. At baseline a CHX chip was placed in pocket sites with @entity92 > or = 5 mm. The @entity1 were scheduled to receive RPMT at 3-month intervals with repeated CHX chip placement at sites where the @entity92 remained > or = 5 mm. @entity1 who did not attend the 24-month recall visit or who failed to attend 2 consecutive time frame examinations were excluded from the analyses. RESULTS: The 595 @entity1 included showed a continuous decrease in @entity92 over 2 years of 0.95 mm. After 2 years, 23.2% of @entity1 had at least 2 pockets showing a reduction in @entity92 of 2 mm or more and 58.9% of the sites had been reduced to a @entity92 of < 5 mm. Only 2.9% (n = 57) of the sites showed an increase in @entity92 of > or = 2 mm. Adverse events were mild to moderate in nature and resolved spontaneously without medication. CONCLUSION: The results of this Phase IV or follow-up trial indicate that the adjunctive use of the CHX chip is a clinically safe and effective treatment option for long-term management of @entity7278 .
